Targeting of Any Protein
We target previously 'Undruggable' human proteins; the largest class of human proteins and a driver of multiple cancers and diseases
Our proprietary AI-based platform applies a powerful Generative AI approach to rapidly design Oligos (short, single-stranded RNA or DNA sequences) that have a higher performance when compared to Oligos developed in physical laboratory experiments such as SELEX.
Leveraging recent breakthroughs in mRNA vaccine development and antisense drugs, we design Oligo drugs with a novel moeity: protein binding
WHO WE ARE
A Platform TechBio Company
PentaBind is a platform TechBio company consisting of bioinformaticians, data scientists, biophysicists, engineers and synthetic biology experts, who's CEO is a serial entrepreneur (1x biotech exit). They are backed by the prolific venture capital firm, Entrepreneur First and supported by Panacea Stars and P4SY.
PentaBind
Generative Algorithms and Oligos will unlock the next generation of therapeutics
GET IN TOUCH
Contact us for partnership or investment enquiries, and job opportunities
